Latest Retinitis pigmentosa Stories
Engineered virus will improve gene therapy for blinding eye diseases Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration. Unlike current treatments, the new procedure – which takes...
Author Ingrid Ricks says blinding eye disease pushed her to pursue book writing dream, help teens write and publish their stories SEATTLE, June 13, 2013 /PRNewswire/ -- Hippie Boy: A Girl's Story, a self-published memoir about a feisty teenage girl who escapes her abusive Mormon stepfather and the suffocating religion and poverty at home by joining her dad on the road as a tool-selling vagabond, has hit the New York Times eBook bestseller list. (Photo:...
As Congress has designated 2010-2020 as the “Decade of Vision” to acknowledge the very real public health need and challenge of vision loss, the Pennsylvania Association for the Blind supports vision research. Mechanicsburg, PA (PRWEB) June 07, 2013 The Need Congress has designated 2010-2020 as the “Decade of Vision” to acknowledge the very real public health need and challenge of vision loss. (H. Res. 366 and S. Res. 209) Over 78 million Baby Boomers will be turning 65 over the...
Alex Brown and Erin Gillen join Kim Power Stilson on the TalkWorthy Radio Show to talk about the Utah Vision Walk. Blinding retinal degenerative diseases like retinitis pigmentosa, macular degeneration and Usher syndrome affect more than 10 million Americans, but the Foundation Fighting Blindness is funding cutting-edge studies toward preventions, treatments and cures. Salt Lake City, UT (PRWEB) May 30, 2013 Alex Brown and Erin Gillen, spokespersons for the 5th Annual Utah 5K VisionWalk...
Top Retinal Surgeons Discuss Results and Learnings from Second Human Clinical Trial SEATTLE, May 13, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that the principal investigators met last week to discuss the results of the Company's second human clinical trial. Representatives from each clinical study site were in attendance, and the discussion was moderated by Professor...
OXFORD, England, May 9, 2013 /PRNewswire/ -- -- UshStat(R)video selected to showcase theme of "Life-changing Research" -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013. The ARVO annual meeting is the largest gathering of eye...
Juanita McNeil releases inspirational guide to a pain-free life Richland, WA (PRWEB) April 13, 2013 From suffering abuse as a child to currently battling blindness, Juanita McNeil has overcome many challenges in her life. Though these hardships might keep many people down, they make McNeil strive to find the positives in life. At the age of 46, McNeil is currently attending school for her blindness caused by retinitis pigmentosa. Upon graduation from the Department for the Blind, she has...
ST. PETERSBURG, Fla., Feb. 21, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of...
REUTLINGEN, Germany, Feb. 19, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced results from part of its multicentre study were published today in the peer-reviewed journal Proceedings of the Royal Society B. The research found that, during the course of a three to nine month observation period, functional vision was restored in the majority of nine German patients implanted with a...
Jason Pierce, MSN, MBA, RN for redOrbit.com – Your Universe Online Today the US Food and Drug Administration (FDA) approved an artificial retina that is the first device of its kind to treat a form of progressive blindness that begins in young adulthood. The device will not completely restore vision, but it does allow the wearer to detect differences in light patterns and some shapes from their environment. The Argus II Retinal Prosthesis System, developed by Second Sight Medical...
